Anthropic Trust has appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors, making him the first pharmaceutical industry executive to join the AI lab’s governing body and tipping Trust-appointed directors to a board majority for the first time.

Anthropic Trust appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors on April 14, 2026. With his arrival, directors chosen by the Long-Term Benefit Trust now hold a majority of the seven-person board, crossing a structural governance threshold written into Anthropic’s founding charter but never previously exercised.

Narasimhan is a physician-scientist who has overseen the development and regulatory approval of more than 35 novel medicines and vaccines at Novartis, one of the world’s largest innovative medicines companies. He joins Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.

The Anthropic Long-Term Benefit Trust is a separate legal body that holds a special class of Anthropic stock whose only purpose is electing board directors. Its three trustees hold no equity in Anthropic, draw no salary from it, and are selected by each other rather than by shareholders. The current trustees are Buddy Shah of the Clinton Health Access Initiative, Richard Fontaine of the Center for a New American Security, and Mariano-Florentino Cuéllar of the Carnegie Endowment for International Peace.

The Trust’s explicit mandate is to ensure Anthropic balances financial success with its public benefit mission of developing AI responsibly. Trust Chair Neil “Buddy” Shah said the group specifically sought someone who had stewarded breakthrough science responsibly in a highly regulated setting.

Narasimhan is the third director the Trust has placed on the board, joining existing Trust appointees Jay Kreps and Reed Hastings. Together they now constitute a majority, a shift that gives the Trust’s safety and public benefit mandate structural weight in board decisions for the first time.

The Healthcare Signal

The appointment is not random timing. Anthropic launched Claude for Life Sciences in October 2025 and Claude for Healthcare in January 2026, adding HIPAA-ready infrastructure and tools aimed at clinical, regulatory, and scientific workflows. The company has partnerships with Eli Lilly, Novo Nordisk, and Genmab to explore how AI can compress drug development timelines.

Bringing in a sitting pharma CEO with two decades of regulated-industry experience gives Anthropic direct expertise on the board as Claude’s deployment in clinical and research environments scales. Narasimhan said on LinkedIn that “speed alone isn’t the goal” in healthcare AI, and that “what matters just as much is how these tools are built, governed, and ultimately applied in the real world.”

Daniela Amodei said Narasimhan “brings something rare to our board. He’s overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries. Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic.”

IPO Context

Anthropic’s annualized revenue has surpassed $30 billion, up from $9 billion at end-2025, as demand for Claude models accelerates across enterprise. The company is reportedly weighing an IPO at a $380 billion valuation, and board composition is increasingly scrutinized by investors ahead of a public listing.

The addition of a pharma CEO to a Trust-majority board signals that Anthropic wants its safety-first positioning to translate into credibility with regulated-sector institutional buyers, not just a PR narrative. For a company preparing to access public markets, the governance architecture now matches the story.

Voters in New Jersey’s 11th congressional district are heading to the polls today in a special election that could tighten the Republican House majority to its absolute limit, pitting progressive Democrat Analilia Mejia against Republican Joe Hathaway in a district that Democrats carried by 9 points in 2024.

New Jersey voters are deciding today which party fills the vacant House seat in the 11th congressional district, a race that has drawn national attention because of its direct impact on the GOP’s already razor-thin House majority. Progressive Democrat Analilia Mejia faces Republican Joe Hathaway in a district with roughly 65,000 more registered Democrats than Republicans.

The seat opened when Mikie Sherrill resigned in November 2025 after winning the New Jersey governorship. Cook Political Report rated the race “Solid D,” and a March GBAO poll had Mejia leading 53% to 36%.

Republicans currently hold 218 House seats plus one independent who caucuses with them. Democrats hold 213, with four seats vacant. A Mejia win would reduce the GOP margin further, leaving Speaker Mike Johnson able to lose just two Republican votes on any party-line legislation without Democratic support.

That thinning margin has already been felt in 2026. As crypto.news reported, House Republicans are currently deadlocked over FISA reauthorization and budget reconciliation, consuming legislative bandwidth at the exact moment the CLARITY Act needs Senate Banking Committee attention before midterm politics close the window. A narrower majority makes every defection more consequential.

Who the Candidates Are

Mejia, 48, is a progressive activist and former national political director for Senator Bernie Sanders’ 2020 presidential campaign. She won a crowded February primary by narrowly defeating former Congressman Tom Malinowski, whose campaign was broadly seen as damaged by a $2 million ad blitz from a super PAC aligned with AIPAC that backfired with Democratic primary voters. Sanders, Elizabeth Warren, and Alexandria Ocasio-Cortez endorsed Mejia. Her platform centers on taxing billionaires, universal healthcare, holding Trump accountable, and affordability.

Hathaway, 38, is a Randolph Township councilman and former mayor. He ran as a self-described “commonsense, independent” Republican, repeatedly distancing himself from Trump. “I won’t be a rubber stamp,” he said at an April debate. Trump has not endorsed Hathaway. Hathaway raised $500,000 by end of March versus Mejia’s roughly $1 million, with 70% of his donations coming from $1,000 contributions or higher.

Broader Midterm Implications

Beyond the immediate math, the race is being closely watched as a signal of Democratic voter energy heading into November’s midterms. Special elections in recent years have shown Democrats consistently outperforming their expected margins in suburban districts, and political scientists are watching whether Mejia’s margin tracks or exceeds the district’s historical lean.

The race also tests how effective a progressive candidate can be in an affluent suburban district, with Newsweek noting that her performance could shape Democratic candidate strategy in similar districts across the country heading into the midterm cycle.

The chair of the Commodity Futures Trading Commission (CFTC), Michael Selig, said he would not wait for the appointment of additional commissioners to lead the regulatory agency before moving ahead on rulemaking potentially related to digital assets and prediction markets.

In a Thursday hearing of the House Agriculture Committee, Selig responded to questions from ranking member Angie Craig, who called out the lack of leadership at the CFTC, which normally has a bipartisan panel of five commissioners. The Minnesota representative asked the chair to commit to not finalizing regulations while he is the only commissioner.

“In the interim, we cannot, for the sake of the American people, slow down in our rulemaking,” said Selig. “It’s very important that we get investor protections, consumer protections and safeguards for our markets. And so, I cannot, unfortunately, commit to not do my job that I was appointed to do by the president.”

Selig, who has served as the CFTC’s sole commissioner and chair since December, has come under scrutiny from many lawmakers for unilaterally leading the agency on rules favoring crypto and prediction markets with no bipartisan group of commissioners. As of Thursday, President Donald Trump had not publicly announced any nominations to staff the agency nor signaled he intended to do so.

“We’re going to do more through rulemaking,” said Selig in response to a question on the CFTC’s leadership from Representative Don Davis. “We can’t have the staff deciding on discretion what the rules are.”

Related: CFTC probes oil futures trades tied to Trump’s moves in Iran: Report

The CFTC chair proposed rulemaking in March that could amend or issue new regulations over event contracts on prediction markets. Selig has been outspoken about claiming that the agency has “exclusive jurisdiction” over prediction markets as the companies behind some platforms face state-level lawsuits related to sports betting laws and proposed legislation to crack down on insider trading.

CFTC’s legal fight over prediction market continues

Gaming authorities in several US states have filed lawsuits against prediction market companies like Kalshi and Polymarket, alleging the platforms offered sports betting in violation of state laws.

New Mexico Representative Gabe Vasquez questioned Selig at Thursday’s hearing with a visual aid showing that bets on event contracts and through state-level gaming “aren’t much of a difference, yet they are regulated completely differently.” He accused the CFTC of using “loopholes” to bypass state laws and requirements for prediction markets, causing some jurisdictions to miss out on revenue.

“The CFTC was not created or intended to regulate sports gambling,” said Vasquez, adding:

“Are we regulating real economic risk, or are we allowing prediction markets to steal billions of dollars in an unregulated free-for-all, with no consumer protection as Congress and the CFTC turns a blind eye?”

Companies like Kalshi have argued that they are under the sole jurisdiction of the CFTC. This argument led the company to court wins in Arizona and New Jersey, where this month judges blocked state officials from taking action against Kalshi.

Magazine: Should users be allowed to bet on war and death in prediction markets?